The effect of surface modification of mesoporous silica micro-rod scaffold on immune cell activation and infiltration

Biomaterials

Volumn 83, Issue , 2016, Pages 249-256

  Li, Weiwei Aileen ^a,b   Lu, Beverly Ying ^a,b   Gu, Luo ^a,b   Choi, Youngjin ^c   Kim, Jaeyun ^c   Mooney, David J ^a,b  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD UNIVERSITY   (United States)

^c Sungkyunkwan University   (South Korea)

Author keywords

Acute inflammation; Inflammasome; Mesoporous silica; Poly(ethylene glycol); RGD

Indexed keywords

CELLS; CHEMICAL ACTIVATION; CYTOLOGY; MESOPOROUS MATERIALS; PATHOLOGY; POLYETHYLENE GLYCOLS; SILICA; SURFACE CHEMISTRY; SURFACE TREATMENT; VACCINES;

ACUTE INFLAMMATION; BIOMATERIAL SCAFFOLDS; DESIGN AND DEVELOPMENT; IMMUNE RESPONSE; INFLAMMASOME; INNATE IMMUNES; MATERIAL-BASED; MESOPOROUS SILICA;

SCAFFOLDS (BIOLOGY);

1,1' DIOCTADECYL 3,3,3',3' TETRAMETHYLINDOCARBOCYANINE; DOCOSAHEXAENOIC ACID; FATTY ACID DERIVATIVE; LOW DENSITY LIPOPROTEIN; NANOPARTICLE; RESOLVIN D1; UNCLASSIFIED DRUG; CARRIER PROTEIN; CRYOPYRIN; CYTOKINE; INFLAMMASOME; NLRP3 PROTEIN, MOUSE; SILICON DIOXIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN INJURY; BRAIN REGION; CANCER INFILTRATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; FLUORESCENCE; HEMISPHERE; HISTOLOGY; MICROBUBBLE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; ULTRASOUND; ANIMAL; BONE MARROW CELL; C57BL MOUSE; CHEMISTRY; CYTOLOGY; DENDRITIC CELL; METABOLISM; POROSITY; SURFACE PROPERTY; TISSUE SCAFFOLD;

ANIMALS; BONE MARROW CELLS; CARRIER PROTEINS; CYTOKINES; DENDRITIC CELLS; FEMALE; INFLAMMASOMES; MICE, INBRED C57BL; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; POROSITY; SILICON DIOXIDE; SURFACE PROPERTIES; TISSUE SCAFFOLDS;

EID: 84958042796     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.01.026     Document Type: Article

References (53)

1. Dougan M., Dranoff G. Immune therapy for cancer. Annu. Rev. Immunol. 2009, 27:83-117.
2. Li W.A., Mooney D.J. Materials based tumor immunotherapy vaccines. Curr. Opin. Immunol. 2013, 25(2):238-245.
3. Irvine D.J., Swartz M.A., Szeto G.L. Engineering synthetic vaccines using cues from natural immunity. Nat. Mater. 2013, 12(11):978-990.
4. Ali O.A., et al. In situ regulation of DC subsets and T cells mediates tumor regression in mice. Sci. Transl. Med. 2009, 1(8):8-19.
5. Ali O.A., et al. Infection-mimicking materials to program dendritic cells in situ. Nat. Mater. 2009, 8(2):151-158.
6. Ali O.A., et al. Inflammatory cytokines presented from polymer matrices differentially generate and activate DCs. Adv. Funct. Mater. 2013, 23(36):4621-4628.
7. Kim J., et al. Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy. Nat. Biotech. 2015, 33(1):64-72.
8. Sun B., et al. Engineering an effective immune adjuvant by designed control of shape and crystallinity of aluminum oxyhydroxide nanoparticles. ACS Nano 2013, 7(12):10834-10849.
9. Morishige T., et al. The effect of surface modification of amorphous silica particles on NLRP3 inflammasome mediated IL-1beta production, ROS production and endosomal rupture. Biomaterials 2010, 31(26):6833-6842.
10. Mamaeva V., Sahlgren C., Linden M. Mesoporous silica nanoparticles in medicine-recent advances. Adv. Drug Deliv. Rev. 2013, 65(5):689-702.
11. Eisenbarth S.C., Flavell R.A. Innate instruction of adaptive immunity revisited: the inflammasome. EMBO Mol. Med. 2009, 1(2):92-98.
12. Petrilli V., et al. The inflammasome: a danger sensing complex triggering innate immunity. Curr. Opin. Immunol. 2007, 19(6):615-622.
13. Hornung V., et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 2008, 9(8):847-856.
14. Sharp F.A., et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(3):870-875.
15. Niidome T., et al. PEG-modified gold nanorods with a stealth character for in vivo applications. J. Control. Release 2006, 114(3):343-347.
16. Acharya A.P., et al. The modulation of dendritic cell integrin binding and activation by RGD-peptide density gradient substrates. Biomaterials 2010, 31(29):7444-7454.
17. Sutterwala F.S., et al. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 2006, 24(3):317-327.
18. Inaba K., et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 1992, 176(6):1693-1702.
19. Wattendorf U., Merkle H.P. PEGylation as a tool for the biomedical engineering of surface modified microparticles. J. Pharm. Sci. 2008, 97(11):4655-4669.
20. Tobio M., et al. Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm. Res. 1998, 15(2):270-275.
21. VandeVondele S., Vörös J., Hubbell J.A. RGD-grafted poly-l-lysine-graft-(polyethylene glycol) copolymers block non-specific protein adsorption while promoting cell adhesion. Biotechnol. Bioeng. 2003, 82(7):784-790.
22. Zhang P., et al. Zwitterionic gel encapsulation promotes protein stability, enhances pharmacokinetics, and reduces immunogenicity. Proc. Natl. Acad. Sci. 2015, 112(39):12046-12051.
23. Richter A., Åkerblom E. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int. Arch. Allergy Immunol. 1983, 70(2):124-131.
24. Hershfield M.S., et al. Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients. Arthr. Res. Ther. 2014, 16(2):R63.
25. van der Eijk A.A., Vrolijk J.M., Haagmans B.L. Antibodies neutralizing peginterferon alfa during retreatment of hepatitis C. N. Engl. J. Med. 2006, 354(12):1323-1324.
26. Armstrong J.K., et al. Antibody against poly (ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007, 110(1):103-111.
27. Schmidt D.R., Kao W.J. Monocyte activation in response to polyethylene glycol hydrogels grafted with RGD and PHSRN separated by interpositional spacers of various lengths. J. Biomed. Mater. Res. A 2007, 83(3):617-625.
28. Lynn A.D., Kyriakides T.R., Bryant S.J. Characterization of the in vitro macrophage response and in vivo host response to poly(ethylene glycol)-based hydrogels. J. Biomed. Mater. Res. A 2010, 93(3):941-953.
29. Lynn A.D., et al. Temporal progression of the host response to implanted poly(ethylene glycol)-based hydrogels. J. Biomed. Mater. Res. A 2011, 96(4):621-631.
30. Lynn A.D., Bryant S.J. Phenotypic changes in bone marrow-derived murine macrophages cultured on PEG-based hydrogels activated or not by lipopolysaccharide. Acta Biomater. 2011, 7(1):123-132.
31. Swartzlander M.D., et al. Linking the foreign body response and protein adsorption to PEG-based hydrogels using proteomics. Biomaterials 2015, 41:26-36.
32. Garratty G. Progress in modulating the RBC membrane to produce transfusable universal/stealth donor RBCs. Transfus. Med. Rev. 2004, 18(4):245-256.
33. Hamad I., et al. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol. Immunol. 2008, 46(2):225-232.
34. Moghimi S.M., et al. Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead. J. Control Release 2010, 146(2):175-181.
35. Salvador-Morales C., et al. Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials 2009, 30(12):2231-2240.
36. Mosqueira V.C.F., et al. Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. Biomaterials 2001, 22(22):2967-2979.
37. Hao N., et al. In vitro degradation behavior of silica nanoparticles under physiological conditions. J. Nanosci. Nanotechnol. 2012, 12(8):6346-6354.
38. Lin Y.-S., et al. Ultrastable, redispersible, small, and highly organomodified mesoporous silica nanotherapeutics. J. Am. Chem. Soc. 2011, 133(50):20444-20457.
39. Godin B., et al. Tailoring the degradation kinetics of mesoporous silicon structures through PEGylation. J. Biomed. Mater. Res. Part A 2010, 94(4):1236-1243.
40. Kidane A., Park K. Complement activation by PEO-grafted glass surfaces. J. Biomed. Mater. Res. 1999, 48(5):640-647.
41. Arima Y., Toda M., Iwata H. Complement activation on surfaces modified with ethylene glycol units. Biomaterials 2008, 29(5):551-560.
42. Arima Y., et al. Complement activation by polymers carrying hydroxyl groups. ACS Appl. Mater. Interfaces 2009, 1(10):2400-2407.
43. Reddy S.T., et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 2007, 25(10):1159-1164.
44. Bradley A.J.T., S.T., Murad K.L., Mitsuyoshi J., Scott M.D. Interactions of IgM ABO antibodies and complement with methoxy-PEG-modified human RBCs. Transfusion 2001, 41:1225-1233.
45. Cassel S.L., et al. The Nalp3 inflammasome is essential for the development of silicosis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(26):9035-9040.
46. Dostert C., et al. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008, 320(5876):674-677.
47. Guarda G., et al. Differential expression of NLRP3 among hematopoietic cells. J. Immunol. 2011, 186(4):2529-2534.
48. Bauernfeind F., et al. NLRP3 inflammasome activity is negatively controlled by miR-223. J. Immunol. 2012, 189(8):4175-4181.
49. Carroll M.C. The complement system in regulation of adaptive immunity. Nat. Immunol. 2004, 5(10):981-986.
50. Kolla R.V., et al. Complement C3d conjugation to anthrax protective antigen promotes a rapid, sustained, and protective antibody response. PloS One 2007, 2(10):e1044.
51. van Deventer H.W., et al. The inflammasome component NLRP3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells. Cancer Res. 2010, 70(24):10161-10169.
52. Bruchard M., et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat. Med. 2013, 19(1):57-64.
53. Delano M.J., et al. MyD88-dependent expansion of an immature GR-1+ CD11b+ population induces T cell suppression and Th2 polarization in sepsis. J. Exp. Med. 2007, 204(6):1463-1474.